替芬泰对2.2.15细胞分泌HBsAg的影响

Abstract
Figure/Table
References (15)
Related Citation (0)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Tifentai (TFT) on secretion of Hepatitis B surface antigen (HbsAg) in 2.2.15 cells.Methods Hepatitis B virus deoxyribonucleic acid (HBV-DNA) clones were used to transfect human hepatoma cells HepG2 2.2.15 cell line as experimental model,and TFT was prepared into 102,51,25.5 μm solution.Lamivdine (LAM) 218 μm positive control group (referred to as LAM 218 μm group) and virus control group were established,and they were added to 24-well cell culture plates,0.6 ml/well,4 wells per concentration.The solution was changed once every 4 days,and the cell supernatant was collected on the eighth day.The titer of HBsAg in the cell supernatant was determined by enzyme-linked immunosorbent assay (ELISA),and the OD values of the three batches in each group were compared,and the average inhibition rate was recorded.Results The OD value of the LAM 218 μm group was significantly lower than that of the virus control group,and the difference was statistically significant (P<0.05).The OD values of the TFT 102,51,and 25.5 μm group were significantly lower than those of the virus control group,and the differences were statistically significant (P<0.05).The average inhibition rates of the LAM 218 μm,TFT 102,51,and 25.5 μm group were 37.49%,56.26%,47.33%,and 36.82%,respectively.Conclusion TFT can effectively inhibit the secretion of HBsAg,thereby exerting its anti HBV effect,and can provide data support and reference for further research and development of TFT to become a new anti-HBV drug.

Key words： Tifentai 2.2.15 cells Hepatitis B surface antigen

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XIAO Jin-xin
	YAN Yun
	DU Li-bo
	YU Xiu-lan
	CHEN De-sheng
	PAN Yu-jie

Cite this article:

XIAO Jin-xin,YAN Yun,DU Li-bo, et al. Effect of Tifentai on secretion of HBsAg in 2.2.15 cells[J]. 中国当代医药, 2019, 26(27): 41-43.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I27/41

[1]	苗英霞.超敏HBVDNA 在慢性乙型病毒性肝炎中的临床价值研究[D].青岛：青岛大学，2018.
[2]	袁洁.肝靶向马蹄金素衍生物的合成及抗乙肝病毒活性研究[D].贵阳：贵州大学，2015.
[3]	樊慧蓉，慈小燕，李薇，等.抗乙肝候选新药替芬泰的体外转运机制研究[J].药学学报，2016，51（8）：1233-1239.
[4]	冯玥，霍璇，胡金芳，等.替芬泰对HepG2 细胞的线粒体毒性[J].中国药理学通报，2017，33（9）：1248-1252.
[5]	Meng FC，Xu WR，Li YZ，et al.In silico molecular docking study of repensine and bentysrepinine against HBV DNA polymerase[J].Chin Herb Med，2015，25（1）：39-44.
[6]	马骏，徐颖，黄正明，等.苯丙氨酸二肽类化合物190 对小鼠CCl_4 肝损伤的保护作用[J].解放军药学学报，2009，25（5）：383-386.
[7]	徐颖，黄正明，徐必学，等.苯丙氨酸二肽类化合物073 对鸭乙型肝炎病毒DNA 的抑制作用[J].中国新药与临床杂志，2010，29（3）：217-220.
[8]	戴二黑，李敏然.HBsAg 定量检测技术进展及其临床意义[J].世界华人消化杂志，2017，25（26）：2322-2328.
[9]	郑怡娟，余雪平，郭如意，等.慢性HBV 感染者HBsAg/HBV DNA 比率的检测及其临床意义[J].中国人兽共患病学报，2016，32（6）：558-563.
[10]	冉蓉.不同免疫检验方法检测乙肝病毒感染血清标志物的对比观察及对HBsAg、HBeAb 的影响[J].中外医学研究，2018，16（24）：43-44.
[11]	张伶俐.输血前检测传染性疾病相关指标的重要性[J].中国农村卫生，2017，（6）：53，56.
[12]	董冰，马保金，殷晓星.HBV 感染的乳腺癌患者化疗后HBV 血清学标志物及肝功能变化分析[J].中华医院感染学杂志，2019，29（6）：864-867.
[13]	荆敏.乙型肝炎e 抗原血清水平与肝纤维化严重程度之间的关系[D].杭州：浙江大学，2018.
[14]	冯玥，霍璇，胡金芳，等.替芬泰对HepG2 细胞的线粒体毒性[J].中国药理学通报，2017，33（9）：1248-1252.
[15]	盼丽，刘青川，王晨吟，等.替芬泰对HepG2-2.2.15 细胞HBV-DNA 的抑制作用[J].解放军药学学报，2015，31（1）：1-3，9.